MedTrace Logo

AZD2066 Cocktail Study

NCT00930306 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2009-10-27

No results posted yet for this study

Summary

The aims of this study are to examine the effect of repeated doses of AZD2066 and of caffeine, bupropion, tolbutamide, omeprazole, metoprolol and midazolam on the blood concentrations of each other

Conditions

Interventions

DRUG

AZD2066

12 doses, Given as capsule, 2 mg \& 8 mg

DRUG

Caffeine

2 doses, Given as Tablet, 2x50 mg

DRUG

Tolbutamide

2 doses, Given as Tablet, half of 500 mg

DRUG

Omeprazole Tablet, 20 mg

2 doses, Given as Tablet, 20 mg

DRUG

Midazolam Tablet, 7.5 mg

2 doses, Given as Tablet, 7.5 mg

Sponsors & Collaborators

Principal Investigators

  • Biljana Lilja · AstraZeneca R&D, Södertälje, Sweden

  • Simon Constable · ICON Development Solutions, Manchester, UK

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Completion
2009-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00930306 on ClinicalTrials.gov